Answers are grounded in this paper and cite their sources.
Research demonstrates altered immune profiles in glioma, indicating potential for immunotherapy enhancement.
IDH1 mutations and their associated oncometabolite D-2HG remodel the innate lymphoid cell landscape in gliomas, driving an ILC3-biased phenotype with reduced checkpoint receptor expression. These findings identify ILCs as key modulators of glioma immunity and suggest that targeting innate immune pathways could complement existing immunotherapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Erdem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: